Tag: Era

Janus kinase (JAK) inhibitors have been established a leading drug class in a number of chronic skin diseases. Recent data lends to one researcher’s perspective that one JAK inhibitor’s efficacy in eczema sets it in its own class—and another JAK inhibitor’s safety risks are not actually applicable to the rest available in dermatologic care. In […]